Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. reports developments across a laboratory services business and a therapeutic development business. Its laboratory operations provide technical laboratory and genetic testing services, with professional interpretation of results by licensed physicians. Its therapeutic development work focuses on cancer drug candidates using a nanoencapsulation and targeted therapy platform designed for new and existing oncology drugs.
Recurring company news includes operating and financial results, revenue guidance, stock repurchase activity, laboratory-services partnerships, and precision medicine testing initiatives. Clinical updates also cover oncology programs such as FID-007 and FID-022, including disclosures related to head and neck cancer research and presentations at oncology meetings.
Moffitt Cancer Center and Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT), have announced a strategic partnership aimed at advancing cancer treatment. This collaboration combines Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms to accelerate the development of personalized cancer therapies.
Under the agreement, Moffitt will provide Fulgent with priority access to its clinical resources to expedite the advancement of Fulgent’s clinical pipeline. Fulgent's nanoencapsulation technology has already transformed paclitaxel into the soluble FID-007, showing substantial tumor reduction in Phase 1 studies.
The partnership will also co-develop next-generation personalized treatment options, leveraging Moffitt's scientific expertise and Fulgent's nano-particle-based drug development platform and genetic testing capabilities.
Brixton Biosciences has announced a successful Series B funding round, raising $33M. The funds will be used to advance their Neural Ice™ platform, a drug-free, injectable nerve block designed to provide long-lasting pain relief for 3-6 months. This funding will support pivotal clinical studies targeting knee pain from osteoarthritis and knee replacement surgery. The round was led by Schooner Capital, with participation from several other investors. The company also announced the appointment of Dr. Michael Fishman as Chief Medical Officer and industry veteran Reggie Groves to the Board of Directors. The Neural Ice™ platform has received Breakthrough Device Designation from the FDA, and early clinical results are promising.
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced its first quarter 2024 financial results, reporting a total revenue of $64.5 million with core revenue growing 1% year-over-year to $63.2 million. The company reiterated its full-year 2024 core revenue guidance of $280 million. Despite a GAAP loss of $13.5 million, or $0.45 per share, Fulgent showed a non-GAAP loss of $269,000, or $0.01 per share. The adjusted EBITDA loss was $3.2 million, with cash from operations at $7.3 million. Fulgent's cash, cash equivalents, and investments in marketable securities were $846.2 million as of March 31, 2024. The company highlighted strong momentum in Precision Diagnostics and milestones in its therapeutic development business, including progress in clinical testing for lead oncology drug candidate FID-007. Fulgent maintains a positive outlook for the full year 2024, expecting core revenue of approximately $280 million and a strong financial position with ample cash to execute.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.